Pooled Analyses of Phase III Studies of ADS-5102 (Amantadine) Extended-Release Capsules for Dyskinesia in Parkinson’s Disease

Overview of attention for article published in CNS Drugs, March 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
Among the highest-scoring outputs from this source (#42 of 1,304)
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

So far, Altmetric has seen 6 news stories from 6 outlets.

(GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. (Nasdaq:ADMS) today announced that pooled Phase 3 data of GOCOVRI™ (amantadine…

GlobeNewswire 2018-03-15 -- Pooled analyses of GOCOVRI Phase 3 data published in CNS Drugs -- EMERYVILLE, Calif., March 15…

(GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc. ( Nasdaq:ADMS ) today announced that pooled Phase 3 data of GOCOVRI™ (amantadine…

EMERYVILLE, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc.

-- Pooled analyses of GOCOVRI Phase 3 data published in CNS Drugs -- EMERYVILLE, Calif., March 15, 2018 (GLOBE NEWSWIRE) -…

EMERYVILLE, Calif., March 15, 2018 (GLOBE NEWSWIRE) -- Adamas Pharmaceuticals, Inc.